Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours-Reference-Cited by-同舟云学术

Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Published:2023-04-21 Issue:6 Volume:20 Page:372-389
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Mair Maximilian J.^ORCID,Bartsch Rupert,Le Rhun Emilie^ORCID,Berghoff Anna S.,Brastianos Priscilla K.^ORCID,Cortes Javier^ORCID,Gan Hui K.^ORCID,Lin Nancy U.,Lassman Andrew B.,Wen Patrick Y.,Weller Michael^ORCID,van den Bent Martin^ORCID,Preusser Matthias^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://www.nature.com/articles/s41571-023-00756-z.pdf

Reference171 articles.

1. Ehrlich, P. The Harben Lectures, 1907. Experimental researches on specific therapeutics. J. R. Inst. Public Health 15, 321–340 (1907).

2. Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).

3. Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 30, 2183–2189 (2012).

4. Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190–2196 (2012).

5. Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translating the theranostic concept to neuro-oncology: disrupting barriers;The Lancet Oncology;2024-09

2. Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial;Nature Communications;2024-08-07

3. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases;Neuro-Oncology;2024-07-04

4. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03

5. Current status of precision oncology in adult glioblastoma;Molecular Oncology;2024-06-20